Stocks · News reference
bioAffinity Technologies To Present Clinical And Veteran-Focused Data On CyPath Lung At NAVREF 2026 Annual Conference
Presentations demonstrate beneficial role for CyPath Lung in veteran lung cancer careNAVREF 2026 focuses on innovative research to improve healthcare for veteran
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
Shares of BioAffinity Technologies are surging Thursday after securing a key Hong Kong patent for its CyPath Lung diagnostic.
bioAffinity Technologies shares are trading higher after the company announced that the Hong Kong Intellectual Property Department has granted a patent for the proprietary platform technology for predicting the likelihood of lung cancer using flow cytometry and fluorescent markers to characterize cell populations in sputum.